NAFLD familial risk bests FIB-4 in identifying advanced fibrosis in first-degree relatives
Key takeaways:
- Age, diabetes, obesity and a family history of nonalcoholic fatty liver disease with advanced fibrosis informed the NAFLD Familial Risk Score.
- The NAFLD familial risk score outperformed the Fibrosis-4 index.
A familial risk score comprised of age, obesity, type 2 diabetes and family history of nonalcoholic fatty liver disease accurately identified advanced fibrosis among first-degree relatives, according to researchers.
“Emerging data suggest that NAFLD-related liver fibrosis is heritable, and advanced fibrosis may cluster within families,” Daniel Q. Huang, MBBS, a visiting scholar at the NAFLD Research Center at the University of California, San Diego, and colleagues wrote in Clinical Gastroenterology and Hepatology. “A recent prospective study determined that first-degree relatives of NAFLD patients with advanced fibrosis are at higher risk of NAFLD with advanced fibrosis.”
Image: Adobe Stock
They continued, “However, it is unclear how family history may be used to identify first-degree relatives who are at high risk of NAFLD with advanced fibrosis in the clinical setting.”
In a prospective, cross-sectional, familial study, Huang and colleagues aimed to develop and validate a clinically applicable risk score to identify first-degree relative of probands who underwent assessment of liver fibrosis and were at a higher risk for advanced fibrosis.
They enrolled 242 consecutive adult probands from the University of California, San Diego, (derivation cohort) and the University of Helsinki (validation cohort) and 396 first-degree relatives (median age, 47 years; 64% women; BMI 27.6 kg/m2). The cohorts included probands with NAFLD and advanced fibrosis, NAFLD without advanced fibrosis and without NAFLD.
Univariate analysis showed age 50 years or older (1 point), type 2 diabetes (1 point), obesity (2 points) and a family history of a proband with NAFLD and advanced fibrosis (2 points) were “significant predictors” of advanced fibrosis among first-degree relatives in the derivation cohort (adjusted OR = 5; 95% CI, 1.1-23.6). This data informed the NAFLD Familial Risk Score, in which a score of at least 4 points corresponded with a 13% or greater risk for NAFLD with advanced fibrosis.
Among patients in the derivation cohort, the area under the receiver operating characteristic curve (AUC) was 0.85 (95% CI, 0.76-0.92) and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 90.9%, 67.7%, 23.8% and 98.5%, respectively.
In the validation cohort, the NAFLD Familial Risk Score had an AUC of 0.94 (95% CI, 0.89-0.99) and a sensitivity, specificity, PPV and NPV of 90%, 87.3%, 30% and 99.3%, respectively. The score also outperformed the Fibrosis-4 (FIB-4) index in this cohort (AUC = 0.94; 95% CI, 0.88-0.99 vs. AUC = 0.7; 95% CI, 0.51-0.89).
“The NAFLD Familial Risk Score accurately identifies NAFLD with advanced fibrosis in first-degree relatives of probands who have undergone an assessment of liver fibrosis,” Huang and colleagues concluded. “It is simple, does not require a calculator or extensive laboratory investigations and may be a helpful alternative to FIB-4 for screening first-degree relatives. These data may have implications for surveillance in NAFLD.”
Editor’s Note: Although NAFLD has been recently updated to MAFLD, we have retained the original nomenclature here as the study was conducted prior to the official update to the name.
Collapse
Read more about